BioMedNewsBreaks

FridayFeb 20, 2026 3:04 pm

BioMedNewsBreaks — Mangoceuticals, Inc. (NASDAQ: MGRX) Reports 336% Sales Growth for $99 Monthly TRT Program 

Mangoceuticals (NASDAQ: MGRX) operating under the MangoRx and PeachesRx brands, announced initial success for its newly launched all-inclusive injectable testosterone replacement therapy program priced at $99 per month, which includes doctor visits, consultations, lab work and prescribed medication. Since launching in mid-December, month-over-month sales of the injectable TRT program have increased 336% while customer acquisition costs declined 54%, reflecting what the company described as growing demand for convenient hormone health solutions delivered through its telehealth platform. MangoRx expects TRT to serve as a primary growth driver, alongside oral formulations including PRIME by MangoRx powered by Kyzatrex, as it seeks to expand its presence in the global TRT market, estimated at approximately $2.1 billion to $2.2 billion in 2025.…

Continue Reading

FridayFeb 20, 2026 10:40 am

BioMedNewsBreaks – Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Featured in BioMedWire Editorial on CNS and Oncology Momentum

Oncotelic Therapeutics (OTCQB: OTLC) announced its placement in an editorial published by BioMedWire, one of more than 75 brands within the InvestorBrandNetwork. The article, titled “Drug-Delivery Breakthroughs, Cross-Indication Research Accelerate New Momentum in CNS and Oncology Development,” highlights growing pharmaceutical interest in clinical-stage assets supported by human data and features Oncotelic as an example of a diversified clinical-stage company. The editorial notes the company’s recently expanded international intellectual property coverage for OT-101, its proprietary TGF-β antisense therapeutic platform, strengthening protection across neurology, oncology and CNS drug-delivery technologies designed to cross the blood–brain barrier. To view the full press release, visit https://ibn.fm/2SuJ3…

Continue Reading

ThursdayFeb 19, 2026 9:11 am

BioMedNewsBreaks — Cardio Diagnostics Holdings, Inc. (NASDAQ: CDIO) Schedules Investor Conference Call for Feb. 19, 2026 

Cardio Diagnostics Holdings (NASDAQ: CDIO) announced it will host an investor conference call on Feb. 19, 2026, at 3 p.m. Central Time to provide an overview of its precision molecular approach to cardiovascular disease prevention and early detection. The call will include updates on the company commercially available tests, Epi+Gen CHD(TM) and PrecisionCHD(TM), as well as discussion of recent clinical data, reimbursement progress and strategic growth initiatives.  To view the full press release, visit https://ibn.fm/3xwFk  About Cardio Diagnostics  Cardio Diagnostics is an artificial intelligence-powered precision cardiovascular medicine company that makes cardiovascular disease prevention, detection, and management more accessible, personalized, and precise. The Company was formed to further develop and…

Continue Reading

WednesdayFeb 18, 2026 9:50 am

BioMedNewsBreaks – LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT) Appoints Sidney Braun as CEO of Liora Technologies Europe Subsidiary

LIXTE Biotechnology Holdings (NASDAQ: LIXT), a clinical-stage pharmaceutical and med-tech company advancing cancer treatments, announced the appointment of Sidney Braun as Chief Executive Officer of its Liora Technologies Europe Ltd. subsidiary. Braun, who previously facilitated LIXTE’s November 2025 acquisition of Liora’s assets, brings more than 20 years of healthcare operational and strategic advisory experience and will lead advancement of Liora’s LiGHT System, an electronically controlled proton therapy platform designed to enhance tumor treatment. Management said the appointment supports its strategy to scale the technology and pursue a recurring revenue model within the radiotherapy segment of cancer care. To view the…

Continue Reading

WednesdayFeb 18, 2026 9:30 am

BioMedNewsBreaks – Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Featured in BioMedWire Editorial on Late-Stage Biotech M&A Trends

Oncotelic Therapeutics (OTCQB: OTLC) announced its placement in an editorial published by BioMedWire, one of more than 75 brands within the Dynamic Brand Portfolio at IBN (InvestorBrandNetwork), highlighting the growing focus in biotech mergers and acquisitions on de-risked, late-stage assets with clinical validation. The article, titled “Why Late-Stage CNS, Oncology Assets Are Becoming the Hottest Targets in Biotech M&A,” examines how pharmaceutical companies and investors are prioritizing programs with established safety and efficacy data, placing companies such as Oncotelic, with multiple clinical- and late-stage oncology and central nervous system programs, in alignment with current M&A trends as it advances its…

Continue Reading

WednesdayFeb 18, 2026 9:20 am

BioMedNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Receives Japan Patent Allowance for SPC-15 PTSD Candidate10

Silo Pharma (NASDAQ: SILO), a developmental-stage biopharmaceutical company focused on novel formulations and drug delivery systems for traditional therapeutics and psychedelic treatments, announced that the Japan Patent Office has issued a Notice of Allowance for a patent application covering its lead asset, SPC-15, an intranasal therapeutic targeting post-traumatic stress disorder. The application, titled “Compositions and Methods for the Prevention of Stress-Induced Fear, Depression-Like Behavior, and Anxiety-Like Behavior,” includes composition and method claims and expands Silo’s intellectual property portfolio in stress-modulating therapeutics within a key international market, with management noting the allowance supports protection of the Company’s core scientific innovations ahead…

Continue Reading

TuesdayFeb 17, 2026 2:40 pm

BioMedNewsBreaks — NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Completes FDA Type C Meeting for NRX-100 NDA Pathway 

NRx Pharmaceuticals (NASDAQ: NRXP) announced completion of an in-person Type C guidance meeting with the U.S. Food and Drug Administration, attended by leadership from the Division of Psychiatry Products, Office of Neuroscience and Center for Drug Evaluation and Research. Based on oral guidance, the company believes it has a path to file a New Drug Application for NRX-100, a preservative-free ketamine formulation, supported by existing adequate and well-controlled trials and confirmatory evidence from more than 65,000 patients in a Real World Evidence dataset, while also seeking a broader indication for treatment-resistant depression with suicidality. The FDA advised that no additional nonclinical or bridging studies would be required, and…

Continue Reading

TuesdayFeb 17, 2026 10:45 am

BioMedNewsBreaks – Earth Science Tech, Inc. (OTC: ETST) Announces Governance and Capital Structure Initiatives to Advance Institutional Readiness

Earth Science Tech (OTC: ETST) announced a series of strategic initiatives aimed at enhancing transparency, governance and alignment with long-term shareholder value as it advances toward becoming a fully institutional-ready public company. Building on approximately $3.3 million in net income for fiscal 2025 and anticipated $1.4 million in cost savings in fiscal 2026, the company outlined plans to optimize its portfolio through potential divestitures and brand consolidation, introduce advisory shareholder votes on executive compensation and Series B Preferred Stock retirement, rationalize its capital structure and reduce executive and board compensation, as management positions the company for disciplined growth and improved…

Continue Reading

TuesdayFeb 17, 2026 10:35 am

BioMedNewsBreaks – Earth Science Tech, Inc. (OTC: ETST) Engages Semple, Marchal & Cooper as New PCAOB Auditor

Earth Science Tech (OTC: ETST) announced it has engaged Semple, Marchal & Cooper LLP as its new independent Public Company Accounting Oversight Board auditor, citing the need to strengthen its financial governance framework as operations expand across pharmacy compounding, telemedicine and real estate. The board determined that the firm’s broader resources and multidisciplinary expertise align with the company’s growing operational complexity, supporting enhanced auditing efficiencies and oversight as ETST continues scaling its diversified health and wellness portfolio. To view the full press release, visit https://ibn.fm/hEaGE About Earth Science Tech, Inc. Earth Science Tech, Inc. operates as a strategic holding company,…

Continue Reading

TuesdayFeb 17, 2026 10:25 am

BioMedNewsBreaks – Earth Science Tech, Inc. (OTC: ETST) Reports Fiscal Q3 2026 Revenue Up 14% and Net Income Up 341%

Earth Science Tech (OTC: ETST) reported financial and operational results for the third fiscal quarter ended Dec. 31, 2025, with revenue of $8.4 million, up 14.1% year over year, gross profit of $6.4 million reflecting a 76.3% margin, and net income of $910,000, up 341% from the prior-year period. Adjusted EBITDA totaled $1.2 million, total assets increased to $8.1 million, and the company repurchased and retired 3.7 million shares during the first nine months of fiscal 2026, while ending the quarter with $416,000 in cash, $773,000 in working capital and no bank debt as management cited continued operating leverage and…

Continue Reading